Sponsor of the Day:
Jerkmate
https://www.cbm.uam.es/index.php/events/gamma-delta-t-cell-immunotherapy-for-colorectal-cancer/?lang=es%2F
Gamma-delta T cell immunotherapy for colorectal cancer - Centro de Biología Molecular Severo Ochoa
molecular severo ochoagamma deltacell immunotherapycolorectal cancercentro
https://www.precedenceresearch.com/t-cell-immunotherapy-market
T-cell Immunotherapy Market Size to Hit USD 26.53 Billion by 2034
Oct 16, 2025 - The global T-cell immunotherapy market size is estimated to hit around USD 26.53 billion by 2034 increasing from USD 8.43 billion in 2025, with a CAGR of...
cell immunotherapymarket sizehit usd26 53billion
https://hackaday.com/2023/11/27/car-t-cell-immunotherapy-and-the-quiet-hope-for-a-universal-cancer-treatment/
CAR T Cell Immunotherapy And The Quiet Hope For A Universal Cancer Treatment | Hackaday
All of us have to deal with the looming threat of developing cancer during our lifetime, no matter how good our genetics are, or how healthy our lifestyle is....
cell immunotherapycancer treatmentcarquiethope
https://www.skincancer.org/blog/what-its-like-to-experience-immunotherapy-treatment-for-merkel-cell-carcinoma/
A New Frontier: What It’s Like to Experience Immunotherapy Treatment for Merkel Cell Carcinoma
Feb 2, 2024 - How a new immunotherapy treatment combination is helping patients like Luis battle Merkel cell carcinoma, a dangerous skin cancer.
merkel cell carcinomanew frontierimmunotherapy treatmentlikeexperience
https://www.newswise.com/articles/reprogramming-gatekeeper-immune-cell-may-boost-cancer-immunotherapy
Reprogramming ‘Gatekeeper’ Immune Cell May Boost Cancer Immunotherapy | Newswise
Apr 2, 2026 - Explore how the tumor microenvironment interrupts dendritic cells’ mitochondria, but restoring that function enhances anti-tumor immunity and immunotherapy.
immune cellmay boostcancer immunotherapyreprogrammingnewswise
https://www.genengnews.com/news/takeda-snags-cell-genesys-prostate-cancer-immunotherapy-in-320m-agreement/
Takeda Snags Cell Genesys’ Prostate Cancer Immunotherapy in $320M Agreement
Jun 5, 2023 - All development and commercialization rights for this Phase III treatment will transfer to Takeda for $50 million upfront. Takeda Pharmaceutical has bought the...
prostate cancertakedasnagscellimmunotherapy
https://www.cas.org/resources/cas-insights/cancer-immunotherapy-innovations
Innovations in cancer immunotherapy: Bi-specific T cell engagers | CAS
Mar 9, 2026 - Discover how bi-specific T cell engagers offer simpler, safer, and more effective cancer immunotherapy, with potential beyond oncology.
cancer immunotherapycell engagersinnovationsbispecific
https://link.springer.com/article/10.1186/s12964-023-01315-w?error=cookies_not_supported&code=2f596572-57d1-4bf7-897f-9e09b04dccbd
Targeting CD24 as a novel immunotherapy for solid cancers | Cell Communication and Signaling |...
Nov 2, 2023 - Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of s
solid cancerstargetingnovelimmunotherapycell